v3.26.1
Basis of Presentation
12 Months Ended
Apr. 30, 2026
Basis Of Accounting [Abstract]  
BASIS OF PRESENTATION
2.
BASIS OF PRESENTATION
(a)
Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IASB"), ("IFRS Accounting Standards") and include the material accounting policies as described in Note 3.

Certain items have been reclassified in the prior year financial statements to conform to the presentation and classification used in the current year. These reclassifications had no effect on the Company's consolidated operating results, financial position or cash flows.

 

On July 21, 2026, the Board of Directors approved these consolidated financial statements and authorized them for issuance.

Basis of measurement

These consolidated financial statements have been prepared on the historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information.

(b)
Basis of consolidation

These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company:

 

Name of Subsidiary

 

% Equity
Interest -
April 30, 2026

 

% Equity
Interest -
April 30, 2025, and
2024

 

Country of
Incorporation

 

Functional Currency

ImmunoPrecise Antibodies (Canada) Ltd. d/ba/ MindWalk Biologics

 

100%

 

100%

 

Canada

 

Canadian dollar

ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")

 

100%

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Antibodies (N.D.) LTD

 

100%

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Antibodies (MA) LLC

 

100%

 

100%

 

USA

 

U.S. dollar

Talem Therapeutics LLC ("Talem")

 

100%

 

100%

 

USA

 

U.S. dollar

ImmunoPrecise Netherlands B.V.

 

100%

 

100%

 

Netherlands

 

Euro

ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")

 

0%

 

100%

 

Netherlands

 

Euro

BioStrand B.V. d/b/a MindWalk

 

100%

 

100%

 

Belgium

 

Euro

Idea Family BV

 

100%

 

100%

 

Belgium

 

Euro

BioKey BV

 

100%

 

100%

 

Belgium

 

Euro

BioClue BV

 

100%

 

100%

 

Belgium

 

Euro

 

Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with an entity and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation.

(c)
Functional and presentation currency

The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements. The presentation currency of the Company is the Canadian dollar.

Foreign currency translation

Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences.

Foreign currency transactions

Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss.

When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

e)
Disposal of Subsidiary

 

On December 10, 2024, the Company's announced its intent to divest IPA Europe which represents the Company's Oss and Utrecht operation, located in the Netherlands. The transaction closed on August 6, 2025, and management determined that the disposal group met the criteria for classification as held for sale under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations (IFRS 5) on that date. Accordingly, the consolidated statement of loss, comprehensive loss and cash flows have been recast to reflect the impact of the transaction as required under the relevant standards including IFRS 5.

 

The following table summarizes the major classes of line items included in income from discontinued operations, net of tax, as a result of the divestiture of IPA Europe and reclassification to discontinued operations:

 

 

 

 

 

 

 

 

 

Year Ended
April 30,

 

(in thousands)

 

2026
$

 

 

2025
$

 

 

2024
$

 

REVENUE

 

 

4,737

 

 

 

13,894

 

 

 

14,239

 

COST OF SALES

 

 

2,130

 

 

 

6,077

 

 

 

6,278

 

GROSS PROFIT

 

 

2,607

 

 

 

7,817

 

 

 

7,961

 

EXPENSES

 

 

 

 

 

 

 

 

 

Research and development

 

 

125

 

 

 

643

 

 

 

304

 

Sales and marketing

 

 

123

 

 

 

752

 

 

 

687

 

General and administrative

 

 

832

 

 

 

2,658

 

 

 

2,952

 

Amortization of intangible assets

 

 

109

 

 

 

418

 

 

 

602

 

 

 

 

1,189

 

 

 

4,471

 

 

 

4,545

 

Income before other income (expenses) and income taxes

 

 

1,418

 

 

 

3,346

 

 

 

3,416

 

OTHER INCOME (EXPENSES)

 

 

 

 

 

 

 

 

 

Grant income

 

 

6

 

 

 

44

 

 

 

31

 

Interest, accretion and other income

 

 

 

 

 

12

 

 

 

1

 

Unrealized foreign exchange gain (loss)

 

 

(4

)

 

 

(38

)

 

 

10

 

 

 

 

2

 

 

 

18

 

 

 

42

 

Income before income taxes

 

 

1,420

 

 

 

3,364

 

 

 

3,458

 

Income taxes

 

 

(267

)

 

 

(451

)

 

 

(272

)

NET INCOME FROM DISCONTINUED OPERATIONS

 

 

1,153

 

 

 

2,913

 

 

 

3,186

 

 

The following table summarizes the major classes of line items included in the statement of financial position as a result of the divestiture of IPA Europe and reclassification to discontinued operations on August 6,2025:

 

(in thousands)

 

 

ASSETS

 

 

Current assets

 

 

Cash

 

643

 

Amounts receivable, net

 

3,071

 

Inventory

 

1,665

 

Unbilled revenue

 

646

 

Prepaid expense

 

817

 

 

 

 

Deposit on equipment

 

486

 

Property and equipment

 

11,361

 

Intangible assets

 

951

 

Goodwill

 

8,297

 

Total assets

 

27,937

 

LIABILITIES

 

 

Current liabilities

 

 

Accounts payable and accrued liabilities

 

1,047

 

Deferred revenue

 

723

 

Income taxes payable

 

1,030

 

Leases

 

9,429

 

 

 

 

Total liabilities

 

12,229

 

 

 

 

Net assets included in discontinued operations

 

15,708

 

Total liabilities and shareholders’ equity